Alethia Young
Stock Analyst at Cantor Fitzgerald
(3.68)
# 642
Out of 4,814 analysts
141
Total ratings
54.46%
Success rate
30.54%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $7.90 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $11.21 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $563.16 | +50.93% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $0.56 | +3,114.29% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $1.30 | +4,515.38% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.99 | +201.51% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.74 | +492.85% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $118.61 | +175.69% | 7 | Oct 15, 2021 | |
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $230 → $30 | $2.91 | +932.70% | 4 | Jul 23, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $71 | $0.79 | +8,889.62% | 2 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $281 | $489.10 | -42.55% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.06 | +288.35% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.12 | +8,650.00% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $277.29 | +6.39% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $104.53 | -17.73% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $38.32 | +25.26% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.35 | +308.16% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.66 | +160.30% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.17 | +327.35% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $58.22 | +71.76% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $160.53 | +25.21% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $47.45 | +79.14% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $7.76 | +312.37% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $53.79 | +303.42% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $20.58 | +133.24% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $10.70 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $234.75 | -34.40% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $59.12 | +96.21% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $2.86 | +3,606.29% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $7.27 | +285.41% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $199.89 | -58.98% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $284.73 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.49 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.90
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.21
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $563.16
Upside: +50.93%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.56
Upside: +3,114.29%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $1.30
Upside: +4,515.38%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.99
Upside: +201.51%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.74
Upside: +492.85%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $118.61
Upside: +175.69%
Adverum Biotechnologies
Jul 23, 2021
Downgrades: Neutral
Price Target: $230 → $30
Current: $2.91
Upside: +932.70%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $51 → $71
Current: $0.79
Upside: +8,889.62%
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $489.10
Upside: -42.55%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $2.06
Upside: +288.35%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.12
Upside: +8,650.00%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $277.29
Upside: +6.39%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $104.53
Upside: -17.73%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $38.32
Upside: +25.26%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $7.35
Upside: +308.16%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.66
Upside: +160.30%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.17
Upside: +327.35%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $58.22
Upside: +71.76%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $160.53
Upside: +25.21%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $47.45
Upside: +79.14%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $7.76
Upside: +312.37%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $53.79
Upside: +303.42%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $20.58
Upside: +133.24%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $10.70
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $234.75
Upside: -34.40%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $59.12
Upside: +96.21%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $2.86
Upside: +3,606.29%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $7.27
Upside: +285.41%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $199.89
Upside: -58.98%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $284.73
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $1.49
Upside: -